TRADING UPDATES: Bidstack names new COO; Fintel expands deal
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreMon, 30th Dec 2019 15:39
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.
Read more(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.
Read moreFriday 19 August | |
Apax Global Alpha Ltd | Half Year Results |
Kingspan Group PLC | Half Year Results |
Newcrest Mining Ltd | Full Year Results |
Monday 22 August | |
Smoove PLC | Full Year Results |
Tuesday 23 August | |
Aferian PLC | Half Year Results |
John Wood Group PLC | Half Year Results |
Wednesday 24 August | |
Costain Group PLC | Half Year Results |
Lookers PLC | Half Year Results |
Standard Chartered PLC | Half Year Results |
Thursday 25 August | |
Amigo Holdings PLC | Q1 Results |
Anglo Pacific Group PLC | Half Year Results |
Benchmark Holdings PLC | Q3 Results |
CRH PLC | Half Year Results |
Faron Pharmaceuticals Ltd | Half Year Results |
Grafton Group PLC | Half Year Results |
Harbour Energy PLC | Half Year Results |
Hays PLC | Full Year Results |
Hunting PLC | Half Year Results |
Macfarlane Group PLC | Half Year Results |
Morses Club PLC | Full Year Results |
South32 Ltd | Full Year Results |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
Friday 1 July | |
All Star Minerals PLC | GM re name change to Marula Mining |
Monday 4 July | |
Active Energy Group PLC | AGM |
Clean Invest Africa PLC | AGM |
Securities Trust of Scotland PLC | AGM |
Tuesday 5 July | |
Immediate Acquisition PLC | AGM |
Marks & Spencer Group PLC | AGM |
Open Orphan PLC | AGM |
Saga PLC | AGM |
Smartspace Software PLC | AGM |
Young & Co's Brewery PLC | AGM |
Wednesday 6 July | |
Assura PLC | AGM |
ContourGlobal PLC | GM re acquisition by KKR |
GSK PLC | GM re Consumer Healthcare demerger, Haleon listing |
Mining Minerals & Metals PLC | AGM |
PCF Group PLC | GM re director allotment authority |
Puma Alpha VCT PLC | AGM |
Shires Income PLC | AGM |
Sirius Real Estate Ltd | AGM |
Strategic Minerals PLC | AGM |
Worldwide Healthcare Trust PLC | AGM |
Thursday 7 July | |
C&C Group PLC | AGM |
Distil PLC | AGM |
Emmerson PLC | AGM |
Faron Pharmaceuticals Ltd | GM re issuance of shares |
FD Technologies PLC | AGM |
Great Portland Estates PLC | AGM |
Greencare Capital PLC | AGM |
J Sainsbury PLC | AGM |
JPMorgan European Growth & Income PLC | AGM |
Land Securities Group PLC | AGM |
Likewise Group PLC | GM re approval of waiver by takeover/merger panel |
N Brown Group PLC | AGM |
Octopus Apollo VCT PLC | AGM |
Peel Hunt Ltd | AGM |
Pets At Home Group PLC | AGM |
Puma VCT 13 PLC | AGM |
Severn Trent PLC | AGM |
TomCo Energy PLC | AGM |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.
Read moreFaron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.
Read moreFaron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.
Read moreFaron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreFaron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read moreMonday 21 March | |
Photo-Me International PLC | Full Year Results |
Spectral MD Holdings Ltd | Full Year Results |
Sthree PLC | Trading Statement |
Tuesday 22 March | |
Alliance Pharma PLC | Full Year Results |
BioPharma Credit PLC | Full Year Results |
Circassia Group PLC | Full Year Results |
Diaceutics PLC | Full Year Results |
Diurnal Group PLC | Full Year Results |
IQGeo Group PLC | Full Year Results |
Longboat Energy PLC | Full Year Results |
Luceco PLC | Full Year Results |
MaxCyte Inc | Full Year Results |
MP Evans Group PLC | Full Year Results |
Oxford Nanopore Technologies PLC | Full Year Results |
Pebble Group PLC | Full Year Results |
Real Estate Investors PLC | Full Year Results |
Sabre Insurance Group PLC | Full Year Results |
ScS Group PLC | Half Year Results |
Softcat PLC | Half Year Results |
Staffline Group PLC | Full Year Results |
Trustpilot Group PLC | Full Year Results |
YouGov PLC | Half Year Results |
Zotefoams PLC | Full Year Results |
Wednesday 23 March | |
Dignity PLC | Full Year Results |
ECSC Group PLC | Full Year Results |
Henry Boot PLC | Full Year Results |
Judges Scientific PLC | Full Year Results |
Pendragon PLC | Full Year Results |
Saga PLC | Full Year Results |
SigmaRoc PLC | Full Year Results |
Thursday 24 March | |
Arbuthnot Banking Group PLC | Full Year Results |
Atalaya Mining PLC | Full Year Results |
Big Technologies PLC | Full Year Results |
Biome Technologies PLC | Full Year Results |
Bonhill Group PLC | Full Year Results |
Bridepoint Group PLC | Full Year Results |
CVS Group PLC | Half Year Results |
Energean PLC | Full Year Results |
EnQuest PLC | Full Year Results |
Eve Sleep PLC | Full Year Results |
International Public Partnerships Ltd | Full Year Results |
Kin & Carta PLC | Full Year Results |
Next PLC | Full Year Results |
Safestyle UK PLC | Full Year Results |
Secure Trust Bank PLC | Full Year Results |
Sopheon PLC | Full Year Results |
Starwood European Real Estate Ltd | Full Year Results |
WAG Payment Solutions PLC | Full Year Results |
Friday 25 March | |
Electrocomponents PLC | Trading Statement |
Faron Pharmaceuticals Ltd | Full Year Results |
Smiths Group | Half Year Results |
United Utilities Group PLC | Trading Statement |
Wickes Group PLC | Full Year Results |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Publishes research expanding on analysis of a gene mutation in an interferon receptor that is linked to corticosteroid response and outcomes in acute respiratory distress syndrome and Covid-19 patients. Builds on Faron's findings from its phase III 'Interest' trial for Traumakine in ARDS patients. Traumakine is an investigational intravenous interferon beta-1a therapy.
Read more